Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jun;45(6):1919-22.
doi: 10.1128/AAC.45.6.1919-1922.2001.

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

Affiliations

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

A L Barry et al. Antimicrob Agents Chemother. 2001 Jun.

Abstract

The in vitro activity of daptomycin is affected by the concentration of calcium cations in the test medium. Mueller-Hinton broth is currently adjusted to contain 10 to 12.5 mg of magnesium per liter and 20 to 25 mg of calcium per liter, but for testing of daptomycin, greater concentrations of calcium (50 mg/liter) are recommended to better resemble the normal concentration of ionized calcium in human serum. Two levels of calcium were used for broth microdilution tests of 2,789 recent clinical isolates of gram-positive bacterial pathogens. MICs of daptomycin were two- to fourfold lower when the broth contained additional calcium. For most species, however, the percentages of strains that were inhibited by 2.0 microg of daptomycin per ml were essentially identical with the two broth media. Enterococci were the important exception; i.e., 92% were inhibited when tested in calcium-supplemented broth but only 35% were inhibited by 2.0 microg/ml without the additional calcium. This type of information should be considered when selecting criteria for defining in vitro susceptibility to daptomycin.

PubMed Disclaimer

References

    1. Eliopoulos G M, Willey S, Reiszner E, Spitzer P G, Caputo G, Moellering R C. In vitro and in vivo activity of LY146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986;30:532–535. - PMC - PubMed
    1. Fuchs P C, Barry A L, Brown S D. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis. 2000;38:51–58. - PubMed
    1. Jones R N, Barry A L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility test recommendations. Antimicrob Agents Chemother. 1987;31:625–629. - PMC - PubMed
    1. Kennedy S, Chambers H F. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989;33:1522–1525. - PMC - PubMed
    1. Louie M, Simor A E, Szeto S, Patel M, Kreisworth B, Low D E. Susceptibility testing of clinical isolates of Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol. 1992;30:41–45. - PMC - PubMed

Publication types

MeSH terms